Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Insulet (PODD), a medical device company known for its Omnipod Insulin Management System, is identified as a significant growth prospect despite its current Zacks Rank #3 (Hold). The company holds an 'A' rating for both its Growth Style Score and overall VGM (Value, Growth, Momentum) Score, underpinned by a projected 42.9% year-over-year earnings growth for the current fiscal year. Analysts have recently increased fiscal 2025 earnings estimates, with the Zacks Consensus Estimate rising to $4.63 per share, and PODD consistently delivers an average earnings surprise of +19.5%, positioning it as a compelling consideration for growth-focused investors.

Analysis

Insulet Corporation (PODD) demonstrates a compelling growth profile, as indicated by its 'A' ratings for both the Zacks Growth Style Score and the overall VGM Score, despite a neutral Zacks Rank #3 (Hold). The company's fundamental strength is underscored by a projected 42.9% year-over-year earnings growth for the current fiscal year. This forward-looking optimism is reinforced by recent analyst sentiment, with eight upward earnings estimate revisions for fiscal 2025 over the last 60 days, elevating the Zacks Consensus Estimate to $4.63 per share. Furthermore, Insulet has established a track record of exceeding market expectations, evidenced by an average positive earnings surprise of 19.5%. The combination of robust growth forecasts and positive analyst revisions suggests underlying momentum that may present a more bullish case than the top-line 'Hold' rating implies.

Key Decisions for Investors

• Growth-oriented investors should prioritize PODD's strong fundamental metrics, including the 42.9% earnings growth forecast and positive estimate revisions, which may present a more compelling signal than its neutral 'Hold' rating.
• Given the company's history of delivering an average earnings surprise of +19.5%, upcoming earnings reports should be monitored closely as continued outperformance could serve as a significant stock catalyst.
• Investors should conduct further due diligence to understand the factors contributing to the neutral #3 rank, such as valuation or momentum metrics not detailed in the article, to balance the strong growth indicators against potential risks.